Investigational Drug Details
Drug ID: | D391 |
Drug Name: | Sulfamethazine |
Synonyms: | |
Type: | small molecule |
DrugBank ID: | DB01582 |
DrugBank Description: | A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides. |
PubChem ID: | 5327 |
CasNo: | 57-68-1 |
Repositioning for NAFLD: | Yes |
SMILES: | CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1 |
Structure: |
|
InChiKey: | ASWVTGNCAZCNNR-UHFFFAOYSA-N |
Molecular Weight: | 278.33 |
DrugBank Targets: | Dihydropteroate synthase |
DrugBank MoA: | Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides. |
DrugBank Pharmacology: | Sulfamethazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamethazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA. |
DrugBank Indication: | For the treatment bacterial infections causing bronchitis, prostatitis and urinary tract infections. |
Targets: | |
Therapeutic Category: | |
Clinical Trial Progress: | |
Latest Progress: |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Article ID | PMID | Source | Title |
---|